Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

News: Home Page Research

Healthy Diet Linked to Lower Death Rates Among Low-Income Residents in Southeastern U.S.

Monday, June 29th, 2015

Eating a healthy diet was linked with a lower risk of dying from heart disease, stroke, cancer or other diseases among a population of low-income individuals living in the Southeastern U.S., according to research led by Vanderbilt University investigators. Nearly two-thirds of the participants in the study were African-American. The study by first author Danxia […]

Study finds significant drop in new prostate cancer diagnoses

Friday, June 19th, 2015

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force (USPSTF) against routine PSA screening for men. The new research, led by first author Daniel Barocas, M.D., MPH, […]

Exploring Accountable Care Organizations’ impact on cancer screenings

Friday, May 29th, 2015

As health care organizations implement new strategies to improve quality and reduce costs, a physician researcher at VUMC is setting out to identify whether there could be unintended effects. Matthew Resnick, M.D., MPH, assistant professor of Urologic Surgery and Health Policy, has been awarded a $726,000 grant from the American Cancer Society to study the […]

Tools for exploring ‘omics’ data

Thursday, May 21st, 2015

Advances in technology have generated vast amounts of “omics” data: genomic, epigenomic, transcriptomic, proteomic and metabolomic changes for all types of specimens. Bridging the gap between data generation and investigators’ ability to retrieve and interpret data is essential to realize the biological and clinical value of this wealth of information. Bing Zhang, Ph.D., and colleagues […]

VICC research efforts in spotlight at AACR conference

Thursday, April 30th, 2015

Adding an investigational drug to an already approved estrogen blocking therapy appears to be safe and provided clinical benefit for some postmenopausal women with estrogen-positive breast cancer. The research led by Ingrid Mayer, M.D., associate professor of Medicine and clinical director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), was selected for the […]

Cancer signaling pathway blocker

Friday, April 10th, 2015

Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer. Abnormal regulation of this pathway leads to several human malignancies, including small cell lung cancer and pancreatic cancer, and therefore it is a potential drug target for cancer. Small molecules have […]

Micelle “packets” deliver cancer drugs

Friday, April 10th, 2015

Small interfering RNA (siRNA) molecules can suppress tumor growth and target cells otherwise untreatable by conventional therapeutics, but targeted, intracellular delivery is a significant limitation to siRNA translation. To deliver the siRNA molecules into tumor cells, researchers have packaged them in micelles that express folic acid, which is internalized by cancer cells that overexpress folate […]

New driver behind lung cancer progression

Thursday, April 2nd, 2015

Vanderbilt-Ingram Cancer Center investigators have identified the mechanisms used by a gene and its binding protein to drive tumor growth in several forms of cancer, including non-small cell lung cancer. In a report published online recently in the Proceedings of the National Academy of Sciences (PNAS), first author Jun Qian, Ph.D., lead investigator Pierre Massion, M.D., […]

‘Docking stations’ on chromosomes new anti-cancer target

Thursday, March 26th, 2015

Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks. The protein, WDR5, is a “docking station” for a family of transcription factors called MYC that is overexpressed in the majority of malignancies and which contributes to an estimated 100,000 cancer-related deaths […]

Mutations may predict melanoma response to immunotherapies

Thursday, March 12th, 2015

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators. Douglas Johnson, M.D., assistant professor of Medicine, and Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, are co-first authors […]

Next Page »